Search

Your search keyword '"Van Ganse, Eric"' showing total 455 results
Start Over Author "Van Ganse, Eric"
455 results on '"Van Ganse, Eric"'

1. Perceptions of the impact of individual allergic rhinitis symptoms: A survey of ARIA clinical experts

Author

Sara Gil-Mata, MD, Tatiana Teixeira, MD, Anna Bedbrook, BSc, Jean Bousquet, PhD, Bernardo Sousa-Pinto, PhD, Rafael José Vieira, MD, Julijana Asllani, Habib Douagui, Estrella Asayag, Castro Maria Elizabeth, Carlos D. Crisci, René Maximiliano Gomez, Juan Carlos Ivancevich, Edgardo Jares, Jorge Fernando Máspero, Pablo Moreno, Hugo Eduardo Neffen, Mario Emilio Zernotti, Sinthia Bosnic-Anticevich, Kristin Chahhoud Carson, Biljana Cvetkovski, Janet M. Davies, Vicky Kritikos, Robyn O'Hehir, Brian Oliver, House Rachel Tan, Jessica Tattersall, Celia Zubrinich, Werner Aberer, Verena Niederberger-Leppin, Isabella Pali-Schöll, Virginie Doyen, Didier Ebo, Renaud Louis, Philippe Rombaux, Sophie Scheire, Kazi Bennoor, Bruno A. Barreto, Paulo Camargos, Herberto Jose Chong-Neto, Alvaro A. Cruz, Jane da Silva, Guidacci Marta, José Angelo Rizzo, Nelson Rosario Filho, Sarquis Serpa Faradiba, Dirceu Solé, Marilyn Urrutia-Pereira, George Christoff, Mandazhieva-Pepelanova Mariana, Odjakova Cvetanka, Todor A. Popov, Dilyana Vicheva, do Ceu Teixeira Maria, Jacques Bouchard, Jan Brozek, Derek K. Chu, Judah Denburg, Thomas Eiwegger, Paul K. Keith, Teresa To, Susan Waserman, Nancy Abusada, Emilio Alvarez Cuesta, Mario A. Calvo-Gil, Maria Antonieta Guzmán, Tamara Pérez Gomez, Wing Kin Wong Gary, Luo Zhang, Luis Caraballo, Alfonso Cepeda Sarabia, Dieudonné Nyembue, Manuel Soto-Martinez, Neven Miculinic, Davor Plavec, Constantinos Pitsios, Panayiotis Yiallouros, Petr Panzner, Milan Sova, Martina Vachova, Carsten Bindslev-Jensen, Ronald Dahl, Hans-Jorgen Malling, Lars Münter, Lars K. Poulsen, Suppli Ulrik Charlotte, Line Kring Tannert, Bassam Mahboub, Laila Salameh, Ivan Cherrez-Ojeda, de Guevara Karla Robles, Rasha Hassan El-Owaidy, Zeinab A. El-Sayed, Shereen Saad El-Sayed, Elham Hossny, Badr Eldin Mostafa, Kaja Julge, Nils Eric Billo, Patrik Eklund, Marina Erhola, Tari Haahtela, Jussi Karjalainen, Mika Makela, Sanna Toppila-Salmi, Erkka Valovirta, Tuula Vasankari, Isabella Annesi-Maesano, Isabelle Bossé, Melisande Bourgoin-Heck, Denis Charpin, André Coste, Frédéric de Blay, Philippe Devillier, Alain Didier, Anh Tuan Dinh-Xuan, Jean-François Fontaine, Jocelyne Just, Rachel Nadif, Nhân Pham-Thi, Bernard Pigearias, Nicolas Roche, Van Ganse Eric, Ekaterine Chkhartishvili, Amiran Gamkrelidze, Maia Gotua, Sven Becker, Karl-Christian Bergmann, Thomas Bieber, Randolf Brehler, Roland Buhl, Adam M. Chaker, Ulf Darsow, Eckard Hamelmann, Joachim Heinrich, Thomas Keil, Ludger Klimek, Pavel Kolkhir, Susanne Lau, Marcus Maurer, Ralph Mösges, Angelos Neou, Oliver Pfaar, Johannes Ring, Martin Wagenmann, Torsten Zuberbier, Aiste Ramanauskaite, Anja Lingnau, Demetrios Christou, Sophia Neisinger, Xenophon Aggelidis, Jannis Constantinidis, Maria Dimou, Christos Grigoreas, Trisevgeni Kapsali, Michael Katotomichelakis, Stelios Loukides, Michael Makris, Emmanouil Manousakis, Nikolaos Mikos, Aris Pagkalos, Nikolaos G. Papadopoulos, Vasileios Papanikolaou, Giannis Paraskevopoulos, Konstantina Piskou, Emmanuel Prokopakis, Fotios Psarros, Konstantinos Samitas, Sofia Stamataki, Evangelia Stefanaki Lina, Ekaterini Syrigou, Ioanna Tsiligianni, Mina Vallianatou, Dimitrios Vourdas, Paraskevi Xepapadaki, Aspasia Karavelia, Fanny Wai San Ko, Gary Wong, Andor Hirschberg, Helga Kraxner, Kristof Nekam, Stephen Lane, Menachem Rottem, Cristina Artesani Maria, Simona Barbaglia, Bianca Beghé, Beatrice Bilo Maria, Attilio Boner, Matteo Bonini, Sergio Bonini, Fulvio Braido, Luisa Brussino, G Walter Canonica, Lorenzo Cecchi, Giorgio Ciprandi, Enrico Compalati, Gennaro D'Amato, Giulia De Feo, Stefano Del Giacco, Alessandro Fiocchi, Enrico Heffler, Carlo Lombardi, Riccardo Monti, Antonella Muraro, Eustachio Nettis, Stefania Nicola, Giovanni Passalacqua, Vincenzo Patella, Francesca Puggioni, Giovanni Rolla, Antonino Romano, Nicola Scichilone, Massimo Triggiani, Teresa Ventura Maria, Giovanni Viegi, Cristina Boccabella, Mattia Giovannini, Anand Mahesh Padukudru, Tomohisa Iinuma, Ken Ohta, Yoshitaka Okamoto, Kimihiro Okubo, Ruby Pawankar, Daiju Sakurai, Maho Suzukawa, Masao Yamaguchi, Zhanat Ispayeva, Yoon-Seok Chang, Hae-Sim Park, Mona Al-Ahmad, Ieva Cirule, Ineta Grisle, Carla Irani, Philip Rouadi, Fares Zaitoun, Ruta Dubakiene, Regina Emuzyte, Violeta Kvedariene, Brigita Gradauskiene, Arunas Valiulis, Markus Ollert, Farah Hannachi, Dejan Dokic, Amir Hamzah Abdul Latiff, Baharudin Abdullah, S.P. Palaniappan, Kent Woo, Stephen Montefort, Martín Bedolla Barajas, María del Carmen Costa Domínguez, Jesús Guillermo Espinoza Contreras, Jose Miguel Fuentes Pèrez, José Luis Gálvez Romero, María de la Luz Hortensia García Cruz, Sandra González Diaz, Yunuen Rocío Huerta Villalobos, Désiree E. Larenas-Linnemann, Jorge Agustin Luna-Pech, Juan José Matta Campos, Daniela Rivero Yeverino, Mónica Rodríguez González, Eréndira Rodríguez Zagal, Battur Lkhagvaa, Sandra Mavale-Manuel, Abrantes Nunes Elizabete, Niels Chavannes, Wytske J. Fokkens, Gerard Koppelman, Anke-Hilse Maitland-van der Zee, Sietze Reitsma, Ramanathan Chandrasekharan, Osman Yusuf, Maria Susana Repka-Ramirez, Juan Carlos Sisul, José E. Gereda, Marysia T. Recto, Slawomir Bialek, Artur Bialoszewski, Marta Chelminska, Radoslaw Gawlik, Ewa Jassem, Marek Jutel, Piotr Kuna, Maciej Kupczyk, Marcin Moniuszko, Marek Niedoszytko, Filip Raciborski, Jan Romantowski, Boleslaw Samolinski, Krzysztof Specjalski, Pedro Carreiro Martins, Jaime Correia de Sousa, Elisio Costa, Joao A. Fonseca, Olga Lourenço, Mario Morais-Almeida, Margarida Pereira Ana, Frederico Regateiro, Carlos Robalo Cordeiro, Jose Rosado Pinto, Bernardo Sousa-Pinto, Luis Taborda Barata, Ana Maria Todo-Bom, José Vieira Rafael, Daniela Carvalho, Maryam Ali Al-Nesf, Ioana Agache, Camelia Berghea Elena, Roxana Bumbacea, Diana Deleanu, Florin Mihaltan, Carmen Panaitescu Bunu, Musa Khaitov, Leyla Namazova-Baranova, Elena Vishneva, Ali Alshaikh Nada, Sanja Dimic-Janjic, Branislava Milenkovic, De Yun Wang, Martin Hrubiško, Natalija Edelbaher, Maja Jošt, Peter Kopac, Mitja Košnik, Nika Lalek, Antonija Poplas Susic, Irma Rozman Sinur, Tanja Soklic Košak, Nadja Triller, Katja Triller, Jure Urbancic, Mihaela Zidarn, Michael Levin, Paul Potter, Heather Zar, Isam Alobid, Aram Anto, Joan Bartra, Irina Bobolea, Paloma Campo, Vicky Cardona, Maria Carriazo Ana, José Antonio Castillo Vizuete, Tomas Chivato, Ignacio Jesus Davila Gonzalez, Joaquim Mullol, Antonio Nieto Garcia, César Picado, Santiago Quirce, Joaquin Sastre, Leticia de las Vecillas, Mikael Benson, Inger Kull, Marianne van Hage, Magnus Wickman, Nikolai Khaltaev, Yousser Mohammad, Pongsakorn Tantilipikorn, Pakit Vichyanond, Cemal Cingi, Bilun Gemicioglu, Ozlem Goksel, Omer Kalayci, Ali Fuat Kalyoncu, Cem Meço, Koyuncu Ilgim Vardaloglu, Arzu Yorgancioglu, Deniz Eyice Karabacak, Bruce Kirenga, Ian Michael Adcock, Hasan S. Arshad, Mike Bewick, Christine Bond, Christopher Brightling, Andrew Bush, Moïses Calderon, Kian Fan Chung, Adnan Custovic, Ratko Djukanovic, Stephen Durham, John Farrell, David Halpin, Michael Hyland, Sebastian Johnston, Brian Lipworth, Alla Nakonechna, David Price, Graham Roberts, Dermot Ryan, Jürgen Schwarze, Aziz Sheikh, Mike Shields, Samantha Walker, Sian Williams, Igor Kaidashev, Andrii Igorevich Kurchenko, Vladyslav Tsaryk, David Bernstein, Jonathan A. Bernstein, Thomas B. Casale, Sharon Chinthrajah, Mark Dykewicz, Gailen D. Marshall, Eli O. Meltzer, Robert M. Naclerio, Alkis Togias, Elina Toskala, Dana Wallace, Dennis M. Williams, Barbara Yawn, Fernan Caballero-Fonseca, Lan Le Thi Tuyet, and Tran Thien Quan Vu

Subjects
Allergic rhinitis, Survey, Professional-patient relation, Immunologic diseases. Allergy, RC581-607
Abstract

Background: Allergic rhinitis (AR) is a highly prevalent disease. We aimed to assess the symptoms that physicians who see patients with AR perceive as the most bothersome in their patients. Methods: We performed a cross-sectional study based on an online questionnaire sent to all members of the Allergic Rhinitis and its Impact on Asthma (ARIA) initiative. The survey included questions on the physicians' perceptions of patients’ AR symptoms as well as of their own AR symptoms. Results: Among 401 respondents, 155 (38.7%) reported having AR. ARIA members reported nasal symptoms to be the most frequent (89.7%) and bothersome (80.0%) symptoms experienced by themselves. Likewise, nasal symptoms were reported by ARIA members as the most frequent (94.8% in members with AR vs 96.0% in members without AR) and bothersome (57.0% in members with AR vs 67.9% in members without AR) in their patients. We found a significant association (p = 0.001) between physicians’ own symptoms and those perceived as the most bothersome in their patients. Conclusion: Physicians perceive nasal symptoms to be the most frequent and the most bothersome symptoms in AR patients. The physicians' personal experiences with AR may influence their perception of patients’ symptoms.

Published
2024
Full Text
View/download PDF

2. Concepts for the Development of Person-Centered, Digitally Enabled, Artificial Intelligence–Assisted ARIA Care Pathways (ARIA 2024)

Author

Bousquet, Jean, Schünemann, Holger J., Sousa-Pinto, Bernardo, Zuberbier, Torsten, Togias, Alkis, Samolinski, Boleslaw, Bedbrook, Anna, Czarlewski, Wienczyslawa, Hofmann-Apitius, Martin, Litynska, Justyna, Vieira, Rafael José, Anto, Josep M., Fonseca, Joao A., Brozek, Jan, Bognanni, Antonio, Brussino, Luisa, Canonica, G. Walter, Cherrez-Ojeda, Ivan, Cruz, Alvaro A., Vecillas, Leticia de las, Dykewicz, Mark, Gemicioglu, Bilun, Giovannini, Mattia, Haahtela, Tari, Jacobs, Marc, Jacomelli, Cristina, Klimek, Ludger, Kvedariene, Violeta, Larenas-Linnemann, Desiree E., Louis, Gilles, Lourenço, Olga, Leemann, Lucas, Morais-Almeida, Mario, Neves, Ana Luisa, Nadeau, Kari C., Nowak, Artur, Palamarchuk, Yuliia, Palkonen, Susanna, Papadopoulos, Nikolaos G., Parmelli, Elena, Pereira, Ana Margarida, Pfaar, Oliver, Regateiro, Frederico S., Savouré, Marine, Taborda-Barata, Luis, Toppila-Salmi, Sanna K., Torres, Maria J., Valiulis, Arunas, Ventura, Maria Teresa, Williams, Sian, Yepes-Nuñez, Juan J., Yorgancioglu, Arzu, Zhang, Luo, Zuberbier, Jaron, Abdul Latiff, Amir Hamzah, Abdullah, Baharudin, Agache, Ioana, Al-Ahmad, Mona, Al-Nesf, Maryam Ali, Al Shaikh, Nada A., Amaral, Rita, Ansotegui, Ignacio J., Asllani, Julijana, Balotro-Torres, Maria Cristina, Bergmann, Karl-Christian, Bernstein, Jonathan A., Bindslev-Jensen, Carsten, Blaiss, Michael S., Bonaglia, Cristina, Bonini, Matteo, Bossé, Isabelle, Braido, Fulvio, Caballero-Fonseca, Fernan, Camargos, Paulo, Carreiro-Martins, Pedro, Casale, Thomas, Castillo-Vizuete, José-Antonio, Cecchi, Lorenzo, Teixeira, Maria do Ceu, Chang, Yoon-Seok, Loureiro, Claudia Chaves, Christoff, George, Ciprandi, Giorgio, Cirule, Ieva, Correia-de-Sousa, Jaime, Costa, Elisio M., Cvetkovski, Biljana, de Vries, Govert, Del Giacco, Stefano, Devillier, Philippe, Dokic, Dejan, Douagui, Habib, Durham, Stephen R., Enecilla, Maria Lourdes, Fiocchi, Alessandro, Fokkens, Wytske J., Fontaine, Jean-François, Gawlik, Radoslaw, Gereda, Jose E., Gil-Mata, Sara, Giuliano, Antonio F.M., Gotua, Maia, Gradauskiene, Brigita, Guzman, Maria Antonieta, Hossny, Elham, Hrubiško, Martin, Iinuma, Tomohisa, Irani, Carla, Ispayeva, Zhanat, Ivancevich, Juan Carlos, Jartti, Tuomas, Jeseňák, Miloš, Julge, Kaja, Jutel, Marek, Kaidashev, Igor, Bennoor, Kazi S., Khaltaev, Nicolai, Kirenga, Bruce, Kraxner, Helga, Kull, Inger, Kulus, Marek, Kuna, Piotr, Kupczyk, Maciej, Kurchenko, Andriy, La Grutta, Stefania, Lane, Stephen, Miculinic, Neven, Lee, Sang Min, Le Thi Tuyet, Lan, Lkhagvaa, Battur, Louis, Renaud, Mahboub, Bassam, Makela, Mika, Makris, Michael, Maurer, Marcus, Melén, Eric, Milenkovic, Branislava, Mohammad, Yousser, Moniuszko, Marcin, Montefort, Stephen, Moreira, Andre, Moreno, Pablo, Mullol, Joaquim, Nadif, Rachel, Nakonechna, Alla, Navarro-Locsin, Cecilia Gretchen, Neffen, Hugo E., Nekam, Kristof, Niedoszytko, Marek, Nunes, Elizabete, Nyembue, Dieudonné, O’Hehir, Robyn, Ollert, Markus, Ohta, Ken, Okamoto, Yoshitaka, Okubo, Kimihiro, Olze, Heidi, Padukudru, Mahesh Anand, Palomares, Oscar, Pali-Schöll, Isabella, Panzner, Petr, Palosuo, Kati, Park, Hae S., Passalacqua, Giovanni, Patella, Vincenzo, Pawankar, Ruby, Pétré, Benoît, Pitsios, Constantinos, Plavec, Davor, Popov, Todor A., Puggioni, Francesca, Quirce, Santiago, Raciborski, Filip, Ramonaité, Agné, Recto, Marysia, Repka-Ramirez, Susana, Roberts, Graham, Robles-Velasco, Karla, Roche, Nicolas, Rodriguez-Gonzalez, Monica, Romualdez, Joel A., Rottem, Menachem, Rouadi, Philip W., Salapatas, Marianella, Sastre, Joaquin, Serpa, Faradiba S., Sayah, Zineb, Scichilone, Nicola, Senna, Gianenrico, Sisul, Juan Carlos, Solé, Dirceu, Soto-Martinez, Manuel E., Sova, Milan, Sozinova, Olga, Stevanovic, Katarina, Ulrik, Charlotte Suppli, Szylling, Anna, Tan, Frances M., Tantilipikorn, Pongsakorn, Todo-Bom, Ana, Tomic-Spiric, Vesna, Tsaryk, Vladyslav, Tsiligianni, Ioanna, Urrutia-Pereira, Marilyn, Rostan, Marylin Valentin, Sofiev, Mikhail, Valovirta, Erkka, Van Eerd, Michiel, Van Ganse, Eric, Vasankari, Tuula, Vichyanond, Pakit, Viegi, Giovanni, Wallace, Dana, Wang, De Yun, Waserman, Susan, Wong, Gary, Worm, Margitta, Yusuf, Osman M., Zaitoun, Fares, and Zidarn, Mihaela

Published
2024
Full Text
View/download PDF

7. Potential Severe Asthma Hidden in UK Primary Care

Author

Ryan, Dermot, Heatley, Heath, Heaney, Liam G., Jackson, David J., Pfeffer, Paul E., Busby, John, Menzies-Gow, Andrew N., Jones, Rupert, Tran, Trung N., Al-Ahmad, Mona, Backer, Vibeke, Belhassen, Manon, Bosnic-Anticevich, Sinthia, Bourdin, Arnaud, Bulathsinhala, Lakmini, Carter, Victoria, Chaudhry, Isha, Eleangovan, Neva, FitzGerald, J. Mark, Gibson, Peter G., Hosseini, Naeimeh, Kaplan, Alan, Murray, Ruth B., Rhee, Chin Kook, Van Ganse, Eric, and Price, David B.

Published
2021
Full Text
View/download PDF

15. Development of the International Severe Asthma Registry (ISAR): A Modified Delphi Study

Author

Bulathsinhala, Lakmini, Eleangovan, Nevaashni, Heaney, Liam G., Menzies-Gow, Andrew, Gibson, Peter G., Peters, Matthew, Hew, Mark, van Boven, Job F.M., Lehtimäki, Lauri, van Ganse, Eric, Belhassen, Manon, Harvey, Erin S., Perez de Llano, Luis, Maitland-van der Zee, Anke H., Papadopoulos, Nikolaos G., FitzGerald, J. Mark, Porsbjerg, Celeste, Canonica, G. Walter, Backer, Vibeke, Rhee, Chin Kook, Verhamme, Katia M.C., Buhl, Roland, Cosio, Borja G., Carter, Victoria, Price, Chris, Le, Thao, Stagno d’Alcontres, Martina, Gopalan, Gokul, Tran, Trung N., and Price, David

Published
2019
Full Text
View/download PDF

28. Quality standards in respiratory real-life effectiveness research: the REal Life EVidence AssessmeNt Tool (RELEVANT): report from the Respiratory Effectiveness Group—European Academy of Allergy and Clinical Immunology Task Force

Author

Roche, Nicolas, Campbell, Jonathan D., Krishnan, Jerry A., Brusselle, Guy, Chisholm, Alison, Bjermer, Leif, Thomas, Mike, van Ganse, Eric, van den Berge, Maarten, Christoff, George, Quint, Jennifer, Papadopoulos, Nikolaos G., and Price, David

Published
2019
Full Text
View/download PDF

29. Rhinitis associated with asthma is distinct from rhinitis alone: TARIA‐MeDALL hypothesis

Author

Bousquet, Jean, Melén, Erik, Haahtela, Tari, Koppelman, Gerard, Togias, Alkis, Valenta, Rudolf, Akdis, Cezmi, Czarlewski, Wienczyslawa, Rothenberg, Marc, Valiulis, Arunas, Wickman, Magnus, Vichyanond, Pakit, Moniuszko, Marcin, Ėmužytė, Regina, Bush, Andrew, Chu, Derek K, Viegi, Giovanni, Wallace, Dana, Durham, Stephen, Wang, De Yun, Vandenplas, O., Just, Jocelyne, Carlsen, Karin C. Lodrup, Passalacqua, Giovanni, Williams, Siân, Linnemann, Désirée Larenas, Loureiro, Cláudia Chaves, Sagara, Hironori, Worm, Margitta, Yiallouros, Panayiotis, Yusuf, Osman, Zaitoun, Fares, Bonini, Matteo, Hrubiško, Martin, Cingi, C., Dykewicz, Mark, Zernotti, Mario, Calderon, Moises, Halpin, David M.G., Zidarn, Mihaela, Patella, Vincenzo, Sheikh, Aziz, Zuberbier, Jaron, Papadopoulos, Nikolaos, Louis, Renaud, Suppli Ulrik, Charlotte, Fonseca, João P., Zuberbier, Torsten, Anto, M. J., Costa, Elisio, Eiwegger, Thomas, Bosnic-Anticevich, Sinthia, Cruz, Alvaro, Sousa, Jaime Correia de, Louis-Philippe, Boulet, Erhola, Marina, Cardona, Victoria, Carr, Warner, Gemicioglu, Bilun, Pawankar, Ruby, Fokkens, Wytske, Calvo, Mário, Garcia-Aymerich, J., Mäkelä, Mika J., Hofmann, Maja Ann, Klimek, Ludger, Makris, Michael, Mohamed Sayed, Zeinab, Maurer, Marcus, D'Amato, G., Momas, Isabelle, Siroux, Valérie, Almeida, Mário Morais, Corrigan, Chris, Mullol, Joaquim, Montefort, Stephen, Jutel, Marek, Pham Thi, Nhan, Hossny, Elham, Akdis, Mubeccel, Pfaar, Oliver, Ventura, Maria Teresa, Regateiro, Frederico S., Bindslev-Jensen, Carsten, Ring, Johannes, Bustamante, Mariona, Pinto, Bernardo Sousa, Kaidashev, Igor, Guerra, Stefano, Standl, Marie, Sunyer, J., Keil, Thomas, Barata, Luís Taborda, Camargos, Paulo, Weiss, Scott, Naclerio, Robert, Yorgancıoglu, Arzu, Zhang, Luo, Nadeau, Kari, Abdul Latiff, Amir, Aberer, Werner, Heinrich, Joachim, Sisul, Juan, Nunes, Elizabete, Plavec, Davor, Agache, Ioana, Al-Ahmad, Mona, Serpa, Faradiba, Alobid, Isam, Kalayci, Omer, Giacco, S. Del, Fiocchi, Alessandro, Ansotegui Zubeldia, Ignacio Javier, Custovic, Adnan, Martins, Pedro Carreiro, Rouadi, Philip, Arshad, Syed Hasan, Asayag, Estrella, Bárbara, Cristina, Abdullah, Baharudin, Tomazic, Peter Valentin, Popov, T. A., Sayah, Zineb, Lkhagvaa, Battur, Nyembue Tshipukane , Dieudonne, Thomas, Mike, Bennoor, Kazi Saifuddin, Fyhrquist, Nanna Theresia, Irani, Carla, Berghea, Elena Camelia, De Blay, Frédéric, Toppila-Salmi, Sanna Katriina, Bergmann, Karl-Christian, Bernstein, D., Bewick, M., Casale, Thomas, Scheire, Sophie, Bumbacea, Roxana Silvia, Cepeda Sarabia, Alfonso, Puggioni, Francesca, Chandrasekharan, Ramanathan, Ohta, Ken, Okubo, Kimihiro, Charpin, Denis, Gomez, R Maximiliano, Chen, Y. Z., O'Hehir, Robyn, Cherrez Ojeda, Ivan, Bedbrook, Anna, To, Teresa, Devillier, Philippe, Schmid-Grendelmeier, Peter, Didier, Alain, Repka-Ramirez, María Susana, Teixeira, Maria Do Céu, Ispayeva, Zhanat, Dokic, Dejan, Quirce, Santiago, Douagui , Habib, Ivancevich, Juan Carlos, Gotua, Maia, Todo-Bom, Ana, Blain, Hubert, Guzman, Maria Antonieta, Kalyoncu, Ali Fuat, Hagemann, Jan, Buhl, Roland, Hamamah, Samir, Caraballo, Luis, Jares, Edgardo, Chivato, Tomás, Jartti, Tuomas, Jassem, Ewa, Christoff, George, Julge, Kalev, Ogulur, Ismail, Kardas, Przemyslaw, Doulaptsi, Maria, Kirenga, Bruce, Helga, Kraxner, Kull, Inger, Kulus, Marek, Daniel, Aguilar, Shamji, Mohamed, Kuna, Piotr, Nadif, Rachel, La Grutta, Stefania, Brightling, Chris, Samoliński, Bolesław, Lau, Susanne, Cordeiro, Carlos Manuel Da Silva Robalo, Solé, Dirceu, Le Thi Tuyet, Lan, Recto, Marysia, Ouedraogo, Solange, Halken, Susanne, Levin, Michael, Lipworth, Brian, Lourenço, Olga, Mahboub, Bassam, Niedoszytko, Marek, Sastre, Joaquin, Martinez‐Infante, E., Kupczyk, Maciej, Torres, María Jose, Matricardi, Paolo Maria, Cecchi, Lorenzo, Celedón, Juan C, Miculinic, Neven, Roche, Nicolas, Migueres, Nicolas, Brussino, Luisa, Florin, Mihaltan, Olze, Heidi, Savouré, Marine, Nekam, Kristof, Pali, Isabella, Okamoto, Yoshitaka, Palomares, O., Lemonnier, Nathanaël, Palosuo, Kati, Soto-Martinez, Manuel, Panaitescu, Carmen, Kvedarienė, Violeta, Panzner, P., Braido, Fulvio, Tsiligianni, Ioanna, Rodriguez-Gonzalez, Monica, Scichilone, Nicola, Canonica, Giogio Walter, Romantowski, Jan, Urrutia-Pereira, Marilyn, Filho, Nelson Augusto Rosario, Ollert, Markus W., Rottem, Menachem, Chkhartishvili, Ekaterine, Sova, Milan, Valovirta, Erkka, Mohammad, Yousser, Sperl, Annette, Spranger, Otto, Neffen, Hugo, Stelmach, Rafael, Burte, Emilie, Valentin Rostan, Marylin, Park, Hae-Sim, Van Ganse, Eric, Van Hage, Marianne, Pitsios, Constantinos, Vasankari, Tuula, and uBibliorum

Subjects
IL-33, Multimorbidity, Asthma, Toll-like receptors, Rhinitis
Abstract

Asthma, rhinitis, and atopic dermatitis (AD) are interrelated clinical phenotypes that partly overlap in the human interactome. The concept of “one-airway-one-disease,” coined over 20 years ago, is a simplistic approach of the links between upper- and lower-airway allergic diseases. With new data, it is time to reassess the concept. This article reviews (i) the clinical observations that led to Allergic Rhinitis and its Impact on Asthma (ARIA), (ii) new insights into polysensitization and multimorbidity, (iii) advances in mHealth for novel phenotype definitions, (iv) confirmation in canonical epidemiologic studies, (v) genomic findings, (vi) treatment approaches, and (vii) novel concepts on the onset of rhinitis and multimorbidity. One recent concept, bringing together upper- and lower-airway allergic diseases with skin, gut, and neuropsychiatric multimorbidities, is the “Epithelial Barrier Hypothesis.” This review determined that the “one-airway-one-disease” concept does not always hold true and that several phenotypes of disease can be defined. These phenotypes include an extreme “allergic” (asthma) phenotype combining asthma, rhinitis, and conjunctivitis.

Published
2023

30. Cancer incidence and prevalence in cystic fibrosis patients with and without a lung transplant in France

Author

Rousset-Jablonski, Christine, primary, Dalon, Faustine, additional, Reynaud, Quitterie, additional, Lemonnier, Lydie, additional, Dehillotte, Clémence, additional, Jacoud, Flore, additional, Berard, Marjorie, additional, Viprey, Marie, additional, Van Ganse, Eric, additional, Durieu, Isabelle, additional, and Belhassen, Manon, additional

Published
2022
Full Text
View/download PDF

32. Comparative non-persistence in the first year of treatment with oral anticoagulants in patients with atrial fibrillation: A French comprehensive nationwide study

Author

Danchin, Nicolas, primary, Steg, Gabriel, additional, Mahé, Isabelle, additional, Hanon, Olivier, additional, Jacoud, Flore, additional, Nolin, Maëva, additional, Dalon, Faustine, additional, Cotte, François-Emery, additional, Gollety, Sabrina, additional, Van Ganse, Eric, additional, and Belhassen, Manon, additional

Published
2022
Full Text
View/download PDF

33. Antipsychotic prescribing practices in real-life (APPREAL study): Findings from the French National Healthcare System Database (2007–2017)

Author

Rolland, Benjamin, primary, Dalon, Faustine, additional, Gauthier, Noémie, additional, Nourredine, Mikaïl, additional, Bérard, Marjorie, additional, Carton, Louise, additional, Brousse, Georges, additional, Llorca, Pierre-Michel, additional, Jacoud, Flore, additional, Van Ganse, Eric, additional, and Belhassen, Manon, additional

Published
2022
Full Text
View/download PDF

35. Apixaban versus other anticoagulants in patients with nonvalvular fibrillation: a comparison of all-cause and event-related costs in real-life setting in France

Author

Belhassen, Manon, primary, Hanon, Olivier, additional, Steg, Philippe Gabriel, additional, Mahé, Isabelle, additional, Née, Mélanie, additional, Jacoud, Flore, additional, Dalon, Faustine, additional, Cotté, François-Emery, additional, Guitard-Dehoux, Dominique, additional, Marant-Micallef, Claire, additional, Van Ganse, Eric, additional, and Danchin, Nicolas, additional

Published
2022
Full Text
View/download PDF

38. The Inhaler Technique Questionnaire (InTeQ) : Development and Validation of a Brief Patient-Reported Measure

Author

Lizano-Barrantes, Catalina, Garin, Olatz, Dima, Alexandra L., Van Ganse, Eric, de Bruin, Marijn, Belhassen, Manon, Mayoral, K, Pont, Àngels, Ferrer Forés, Maria Montserrat, Lizano-Barrantes, Catalina, Garin, Olatz, Dima, Alexandra L., Van Ganse, Eric, de Bruin, Marijn, Belhassen, Manon, Mayoral, K, Pont, Àngels, and Ferrer Forés, Maria Montserrat

Abstract

There is a need for instruments designed for patients with asthma to self-report their performance of inhaling steps. We aimed to develop an accessible and easy-to-use patient-reported tool for inhaler technique assessment, which could also serve as a training and monitoring resource for any type of inhaler device, and to evaluate its feasibility, validity, and reliability in adults with asthma. The development was based on literature review and pilot testing with clinicians and patients. The Inhaler Technique Questionnaire (InTeQ) asks about the frequency of performing five steps when using inhalers (on a five-point Likert scale). We analyzed data from adults with persistent asthma (n = 361). We examined the measurement model using Mokken scaling analysis, construct validity by assessing hypotheses on expected discrimination among known groups, and reliability based on internal consistency and reproducibility. Means of the InTeQ items were in the range of 0.23-1.61, and coefficients of homogeneity were above the cutoff point, demonstrating the unidimensionality of the scale. Known groups' global score differences were statistically significant between patients reporting having "Discussed in detail" or having "Not discussed/Only in general" the inhaler technique with their healthcare providers (p = 0.023). The Cronbach's alpha coefficient was 0.716, and the intraclass correlation coefficient was 0.775. The InTeQ is a feasible, valid, and reliable instrument for self-reporting inhaler technique on any type of device.

Published
2022

39. Challenges and Opportunities With Routinely Collected Data on the Utilization of Cancer Medicines. Perspectives From Health Authority Personnel Across 18 European Countries

Author

Pisana, Alice, Wettermark, Björn, Kurdi, Amanj, Tubic, Biljana, Pontes, Caridad, Zara, Corinne, Van Ganse, Eric, Petrova, Guenka, Mardare, Ileana, Fürst, Jurij, Roig-Izquierdo, Marta, Melien, Oyvind, Bonanno, Patricia Vella, Banzi, Rita, Markovic-Pekovic, Vanda, Mitkova, Zornitsa, Godman, Brian, Pisana, Alice, Wettermark, Björn, Kurdi, Amanj, Tubic, Biljana, Pontes, Caridad, Zara, Corinne, Van Ganse, Eric, Petrova, Guenka, Mardare, Ileana, Fürst, Jurij, Roig-Izquierdo, Marta, Melien, Oyvind, Bonanno, Patricia Vella, Banzi, Rita, Markovic-Pekovic, Vanda, Mitkova, Zornitsa, and Godman, Brian

Abstract

Background: Rising expenditure for new cancer medicines is accelerating concerns that their costs will become unsustainable for universal healthcare access. Moreover, early market access of new oncology medicines lacking appropriate clinical evaluation generates uncertainty over their cost-effectiveness and increases expenditure for unknown health gain. Patient-level data can complement clinical trials and generate better evidence on the effectiveness, safety and outcomes of these new medicines in routine care. This can support policy decisions including funding. Consequently, there is a need for improving datasets for establishing real-world outcomes of newly launched oncology medicines.Aim: To outline the types of available datasets for collecting patient-level data for oncology among different European countries. Additionally, to highlight concerns regarding the use and availability of such data from a health authority perspective as well as possibilities for cross-national collaboration to improve data collection and inform decision-making.Methods: A mixed methods approach was undertaken through a cross-sectional questionnaire followed-up by a focus group discussion. Participants were selected by purposive sampling to represent stakeholders across different European countries and healthcare settings. Descriptive statistics were used to analyze quantifiable questions, whilst content analysis was employed for open-ended questions.Results: 25 respondents across 18 European countries provided their insights on the types of datasets collecting oncology data, including hospital records, cancer, prescription and medicine registers. The most available is expenditure data whilst data concerning effectiveness, safety and outcomes is less available, and there are concerns with data validity. A major constraint to data collection is the lack of comprehensive registries and limited data on effectiveness, safety and outcomes of new medicines. Data ownership limits data access

Published
2022
Full Text
View/download PDF

40. Treatment of Allergic Rhinitis and Asthma in Primary Care: Dispensations Do Not Align with Prescriptions

Author

Belhassen,Manon, Bérard,Marjorie, Devouassoux,Gilles, Dalon,Faustine, Bousquet,Jean, Van Ganse,Eric, Belhassen,Manon, Bérard,Marjorie, Devouassoux,Gilles, Dalon,Faustine, Bousquet,Jean, and Van Ganse,Eric

Abstract

Manon Belhassen,1 Marjorie Bérard,1 Gilles Devouassoux,2 Faustine Dalon,1 Jean Bousquet,3,4 Eric Van Ganse1,2,5 1Pelyon, Pharmacoepidemiology Lyon, Lyon, France; 2Respiratory Medicine, Croix Rousse Hospital, Lyon, France; 3MACVIA-France, Fondation Partenariale FMC VIA-LR, Montpellier, France; 4INSERM U 1168, VIMA, Ageing and Chronic Diseases Epidemiological and Public Health Approaches, Villejuif, France; 5Research on Health Care Performance RESHAPE, INSERM U1290, University Claude Bernard Lyon 1, Lyon, FranceCorrespondence: Eric Van Ganse, Respiratory Medicine, Croix Rousse Hospital, Lyon, France, Tel +33 472 071 730, Email eric.van-ganse@chu-lyon.frBackground: Appropriate use of effective treatments is required for satisfactory control of allergic symptoms. Coherent medical care -regular prescribing by the same Health Care Professionals- is a preliminary need.Objective: We investigated the numbers of distinct prescribers, the regularity of medical visits, and the agreement between prescriptions and associated dispensations in individual patients with perennial allergic rhinitis (PAR) and asthma.Methods: In primary care electronic health records (EHRs), a cohort of patients with PAR and asthma was identified. Individual EHRs were linked to corresponding claims recording all dispensations. Prescribing patterns were analyzed for the major treatment classes, and the dispensations linked to individual prescriptions were retrieved to compute the proportions of days covered (PDCs) for asthma and PAR therapy.Results: A total of 3654 patients were included, with 62% being female (mean age, 46.1 years). At inclusion, asthma control was not optimal in 51% of the patients and 48% had received oral corticosteroids. The mean interval between successive prescriptions varied between 93 (leukotriene receptor antagonists, LTRAs) and 103 (inhaled corticosteroids, ICS) days, and 97 (antihistamines, AHs) and 103 days (nasal corticosteroids, NCS). On average, individual prescripti

Published
2022

41. Challenges and Opportunities With Routinely Collected Data on the Utilization of Cancer Medicines. Perspectives From Health Authority Personnel Across 18 European Countries

Author

Pisana, Alice, primary, Wettermark, Björn, additional, Kurdi, Amanj, additional, Tubic, Biljana, additional, Pontes, Caridad, additional, Zara, Corinne, additional, Van Ganse, Eric, additional, Petrova, Guenka, additional, Mardare, Ileana, additional, Fürst, Jurij, additional, Roig-Izquierdo, Marta, additional, Melien, Oyvind, additional, Bonanno, Patricia Vella, additional, Banzi, Rita, additional, Marković-Peković, Vanda, additional, Mitkova, Zornitsa, additional, and Godman, Brian, additional

Published
2022
Full Text
View/download PDF

47. Towards Optimum Reporting of Pulmonary Effectiveness Databases and Outcomes (TORPEDO): identifying a core dataset for asthma and COPD studies

Author

van Boven, Job FM, primary, Lucas, Sarah J, additional, Parker, Gary, additional, Kaplan, Alan, additional, Trofor, Antigona, additional, Bonevski, Billie, additional, Kirenga, Bruce J, additional, Ryan, Dermot, additional, Pizzichini, Emilio, additional, van Ganse, Eric, additional, Huang, Erick Wan-Chun, additional, Brakema, Evelyn, additional, Gould, Gillian, additional, Kocks, Janwillem, additional, Alison, Jennifer, additional, Quint, Jennifer K, additional, Soriano, Joan B, additional, Hurst, John, additional, Siddiqi, Kamran, additional, Boydell, Katherine, additional, Miravitlles, Marc, additional, Flores-Valdez, Mario Alberto, additional, Kasteleyn, Marise, additional, FitzGerald, Mark, additional, Boeckmann, Melanie, additional, Chaiton, Michael, additional, Rodriguez, Miguel Roman, additional, Kulkarni, Muralidhar, additional, Roche, Nicolas, additional, Chavannes, Niels, additional, Papadopoulos, Nikolaos G, additional, Behrakis, Panagiotis, additional, Dennis, Sarah, additional, Bassi, Shalini, additional, Williams, Siân, additional, Maher, Toby M, additional, Siddharthan, Trishul, additional, Kamath, Veena, additional, and Verhamme, Katia MC, additional

Published
2021
Full Text
View/download PDF

48. Impact of Therapy Persistence on Exacerbations and Resource Use in Patients Who Initiated COPD Therapy

Author

Dalon, Faustine, Devouassoux, Gilles, Belhassen, Manon, Nachbaur, Gaëlle, Correia Da Silva, Camille, Sail, Lynda, Jacoud, Flore, Chouaid, Christos, Van Ganse, Eric, PELyon, Pharmacoepidemiologie, Lyon, laboratoire du sommeil, CHU Grenoble, GlaxoSmithKline, Glaxo Smith Kline, CIC - Biotherapie - CHU Henri Mondor, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), IMRB - CEPIA/'Clinical Epidemiology And Ageing : Geriatrics, Primary Care and Public Health' [Créteil] (U955 Inserm - UPEC), Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Evaluation et modélisation des effets thérapeutiques, Département biostatistiques et modélisation pour la santé et l'environnement [LBBE], Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 (LBBE), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 (LBBE), and Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)

Subjects
Male, therapy, Respiratory Therapy, persistence, International Journal of Chronic Obstructive Pulmonary Disease, Middle Aged, Patient Acceptance of Health Care, Symptom Flare Up, [SDV.MHEP.PSR]Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract, Bronchodilator Agents, Respiratory Function Tests, Patient Outcome Assessment, Pulmonary Disease, Chronic Obstructive, healthcare resource use, exacerbations, COPD, Humans, Patient Compliance, Female, France, Adrenergic beta-2 Receptor Agonists, Glucocorticoids, Original Research
Abstract

Faustine Dalon,1 Gilles Devouassoux,2,3 Manon Belhassen,1,4 Gaëlle Nachbaur,5 Camille Correia Da Silva,5 Lynda Sail,5 Flore Jacoud,1 Christos Chouaid,6 Eric Van Ganse1,2,41PELyon, PharmacoEpidemiology, Lyon, France; 2Pulmonary Department, Hôpital de la Croix Rousse, Hospices Civils de Lyon, Lyon, France; 3EA 7426, PI3, Inflammation & Immunité de L’épithélium Respiratoire, Université Claude-Bernard-Lyon1, Lyon, France; 4EA 7425 HESPER Health Services and Performance Research, Université Claude-Bernard-Lyon1, Lyon, France; 5GlaxoSmithKline France, Pharmaco Epidemiology and Health Economics and Outcomes Research, Rueil-Malmaison, France; 6Pulmonary Department, CHI de Créteil, Créteil, FranceCorrespondence: Faustine DalonPELyon, Immeuble Le Solaris, 210 Avenue Jean Jaurès, Lyon 69007, FranceTel +33 481 099 605Email faustine.dalon@pelyon.frPurpose: This study assessed therapy persistence in patients with chronic obstructive pulmonary disease (COPD) in France, and the impact of non-persistence on exacerbations and described COPD-related healthcare resource use (HRU).Methods: Patients aged ≥45 years who received ≥1 dispensed bronchodilator per quarter over three consecutive quarters between 2007 and 2014 and initiated specific COPD therapy were selected from the Echantillon Généraliste des Bénéficiaires (EGB) database. Persistence, defined as the absence of dispensing gaps of >90 days, was measured at 12 months. Exacerbations were compared between persistent and non-persistent patients during follow-up after patient matching and adjustment for confounding factors. COPD-related HRU during follow-up was described.Results: Among 4020 patients with COPD, 2164 initiated a specific therapy. Of these, 54.4% stopped treatment within 12 months. Persistence with all COPD therapy regimens was low, particularly for inhaled corticosteroid (ICS; 25.6%) and ICS/twice-daily long-acting beta-agonist (39.4%) regimens. Among 721 persistent patients who were matched with 721 non-persistent patients, there was no difference in the number of moderate or severe exacerbations at 12 months. However, medical procedures (for instance, pulmonary function testing and chest X-rays) were more frequently observed among persistent patients than among non-persistent patients, suggesting worse disease severity.Conclusion: Patients receiving specific treatment(s) for COPD demonstrated low persistence for all examined therapy regimens, with no clear impact of persistence status on the frequency of exacerbations at 12 months.Keywords: COPD, therapy, persistence, exacerbations, healthcare resource use

Published
2019
Full Text
View/download PDF

49. Dual versus triple therapy in patients hospitalized for COPD in France: a claims data study

Author

Dalon,Faustine, Roche,Nicolas, Belhassen,Manon, Nolin,Maëva, Pegliasco,Hervé, Deslée,Gaëtan, Housset,Bruno, Devillier,Philippe, Van Ganse,Eric, PELyon, Pharmacoepidemiologie, Lyon, Mucoviscidose et bronchopathies chroniques : biopathologie et phénotypes cliniques (EA 2511), Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Descartes - Paris 5 (UPD5), Hôpital Européen de Marseille (HEM), Hôpital Maison Blanche, Centre Hospitalier Universitaire de Reims (CHU Reims), Pathologies Pulmonaires et Plasticité Cellulaire - UMR-S 1250 (P3CELL), Université de Reims Champagne-Ardenne (URCA)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Hôpital Foch [Suresnes], Health Service and Performance Research (HESPER), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon, Laboratoire de Médecine Respiratoire [HCL - Hôpital de la Croix Rousse, Lyon], Hôpital de la Croix-Rousse [CHU - HCL], Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Aix-Marseille Université - Institut universitaire de technologie (IUT AMU), Aix Marseille Université (AMU), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Reims Champagne-Ardenne (URCA), Evaluation et modélisation des effets thérapeutiques, Département biostatistiques et modélisation pour la santé et l'environnement [LBBE], Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 (LBBE), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 (LBBE), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS), and dormoy, valerian

Subjects
Male, Time Factors, Databases, Factual, [SDV]Life Sciences [q-bio], Cost-Benefit Analysis, Muscarinic Antagonists, International Journal of Chronic Obstructive Pulmonary Disease, Drug Costs, Pulmonary Disease, Chronic Obstructive, Patient Admission, exacerbations, Adrenal Cortex Hormones, COPD, Humans, Adrenergic beta-2 Receptor Agonists, Lung, ComputingMilieux_MISCELLANEOUS, Original Research, Aged, Aged, 80 and over, therapy, health care resource use, persistence, Middle Aged, Bronchodilator Agents, [SDV] Life Sciences [q-bio], Treatment Outcome, Disease Progression, Health Resources, Drug Therapy, Combination, Female, France, Administrative Claims, Healthcare
Abstract

Faustine Dalon,1 Nicolas Roche,2 Manon Belhassen,1 Maëva Nolin,1 Hervé Pegliasco,3 Gaëtan Deslée,4 Bruno Housset,5 Philippe Devillier,6 Eric Van Ganse1,7–81Pharmacoepidemiology Department, PELyon, Lyon, France; 2Respiratory Medicine, Cochin Hospital, AP-HP and Paris Descartes University (EA2511), Sorbonne Paris Cité, Paris, France; 3Pulmonary Department, European Hospital, Marseille, France; 4Pulmonary Department, INSERM U1250, Maison Blanche University Hospital, Reims, France; 5Pulmonary Department, CHI de Créteil, University Paris Est Créteil, Créteil, France; 6Department of Airway Diseases, UPRES EA 220, Foch Hospital, Paris-Saclay University, Suresnes, France; 7EA 7425 Hesper Health Services and Performance Research, Claude-Bernard University, Lyon, France; 8Respiratory Medicine, Croix-rousse Hospital, Lyon, FranceCorrespondence: Faustine DalonPELyon, 11 Rue Guillaume Paradin, Lyon 69008, FranceTel +33 47 877 1024Fax +33 47 877 8660Email faustine.dalon@univ-lyon1.frPurposes: Following a hospitalization for COPD, dual and triple therapies were compared in terms of persistence and relations with outcomes (exacerbations, health care resource use and costs).Methods: This was a historical observational database study. All patients aged ≥45 hospitalized for COPD between 2007 and 2015 were identified in a 1/97th, random sample of French claims data. Patients receiving dual therapy within 60 days after hospitalization were compared to patients receiving triple therapy, after propensity score matching on disease severity.Results: Of the 3,089 patients hospitalized for COPD, 1,538 (49.8%) received either dual or triple therapy in the 2 months following inclusion, and 1,500 (48.6%) had at least 30 days of follow-up available; 846 (27.4%) received dual therapy, and 654 (21.2%) received triple therapy. After matching, the number of exacerbations was 2.4 per year in the dual vs 2.3 in the triple group (p=0.45). Among newly treated patients (n=206), persistence at 12 months was similar in the dual and triple groups (48% vs 41%, respectively, p=0.37). As compared to patients on dual therapy, more patients on triple therapy received oral corticosteroids (49.1 vs 40.4%, p=0.003) or were hospitalized for any reason (67%vs 55.8%, p=0.0001) or for COPD (35.3 vs 25.1%, p=0.0002) during follow-up. Cost of care was higher for patients on triple than for those on dual therapy (€11,877.1 vs €9,825.1, p=0.01).Conclusion: Following hospitalizations for COPD, patients on dual and triple therapy experienced recurrent exacerbations, limited adherence to therapies and high cost of care. Patients on triple therapy appeared more severe than those on dual therapy, as reflected by exacerbations and health care resource use.Keywords: COPD, therapy, persistence, exacerbations, health care resource use

Published
2019
Full Text
View/download PDF

50. EvaluatioN of ApiXaban in strOke and systemic embolism prevention in patients with non‐valvular atrial fibrillation in clinical practice Setting in France, rationale and design of the NAXOS: SNIIRAM study

Author

Picard, Fabien, Van Ganse, Eric, Ducrocq, Gregory, Danchin, Nicolas, Falissard, Bruno, Hanon, Olivier, Belhassen, Manon, Ginoux, Marine, Lefevre, Cinira, Cotte, François‐Emery, Mahé, Isabelle, and Steg, Philippe G.

Subjects
Male, Pyridones, Trial Designs, Embolism, apixaban, Administration, Oral, vitamin‐K antagonists, Atrial Fibrillation, Humans, Aged, Retrospective Studies, Clinical Trials as Topic, Dose-Response Relationship, Drug, systemic embolism, non‐vitamin K antagonist oral anticoagulants, Incidence, Stroke, Survival Rate, Treatment Outcome, major bleeding, Pyrazoles, Female, France, non‐valvular atrial fibrillation, Factor Xa Inhibitors, Follow-Up Studies
Abstract

Non‐vitamin K antagonists oral anticoagulants (NOACs) have recently challenged vitamin‐K antagonists (VKAs) for stroke and systemic embolism prophylaxis in patients with non‐valvular atrial fibrillation (NVAF). Nevertheless, little information is available in routine clinical practice for France. The aim of this study is to describe the effectiveness and safety of apixaban, rivaroxaban, dabigatran or VKAs in routine clinical practice in adult NVAF patients for the prevention of stroke and systemic embolism in France. The NAXOS study is a nationwide observational retrospective cohort generated from the French national healthcare insurance database (SNIIRAM—a comprehensive in‐ and outpatient healthcare consumption database), consisting of eight distinct sub‐cohorts of anticoagulant‐naive or anticoagulant‐experienced patients diagnosed with NVAF, newly initiated with either NOACs (dabigatran, rivaroxaban or apixaban) or VKAs. Patients will be included if initiating a new anticoagulant treatment for AF during the study period from 1 January 2014 to 31 December 2016. Primary effectiveness outcome will be the incidence of stroke or systemic thromboembolic events; primary safety outcome will be the incidence of major bleeding during the exposure period. The NAXOS study will provide routine clinical practice data on the effectiveness and safety profiles of apixaban vs other NOACs and VKAs in the prevention of stroke and systemic embolism in adult patients with NVAF in clinical practice conditions in France.

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results